Compare ARVN & ADSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | ADSE |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | Ireland |
| Employees | N/A | 302 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 691.4M |
| IPO Year | 2018 | N/A |
| Metric | ARVN | ADSE |
|---|---|---|
| Price | $8.96 | $11.74 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $15.05 | N/A |
| AVG Volume (30 Days) | ★ 854.3K | 2.9K |
| Earning Date | 05-04-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $549.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $7.89 |
| 52 Week High | $14.22 | $13.90 |
| Indicator | ARVN | ADSE |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 43.77 |
| Support Level | $7.35 | $11.05 |
| Resistance Level | $10.18 | $12.33 |
| Average True Range (ATR) | 0.51 | 0.64 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 23.34 | 54.59 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.